

# GP47

## Management of Critical- and Significant-Risk Results

This guideline provides current best practice recommendations for developing and implementing a policy and procedures for the identification, reporting, and management of critical- and significant-risk laboratory results. Emphasis is placed on management responsibilities such as development of the policy, the process, procedures, job descriptions, and monitoring systems that ensure effective reporting and compliance with regulatory requirements.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in clinical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing clinical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are addressed according to the consensus process by a committee of experts.

## Appeals Process

If it is believed that an objection has not been adequately addressed, the process for appeals is documented in the CLSI Standards Development Policies and Processes.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute  
950 West Valley Road, Suite 2500  
Wayne, PA 19087 USA  
P: 610.688.0100  
F: 610.688.0700  
[www.clsi.org](http://www.clsi.org)  
[standard@clsi.org](mailto:standard@clsi.org)

This is a preview. [Click here to purchase the full publication.](#)

## Management of Critical- and Significant-Risk Results

Andrew N. Young, MD, PhD  
Anand Dighe, MD, PhD  
Graham Beastall, PhD, FRCPath  
Lydia C. Contis, MD  
Pilar Fernandez-Calle, MD, PhD  
Christine M. Gryko, MT(ASCP)  
Peter Heseltine, MD, FACP, FACB, FIDSA  
Andrea Rita Horvath, MD, PhD

Devery Howerton, PhD, MS, MT(ASCP)SI  
Neal Kachalia, MT(ASCP), DLM, MBA  
Michael J. Misialek, MD  
Raouf E. Nakhleh, MD  
Jennifer F. Rhamy, MBA, MA, MT(ASCP), SBB, HP  
Susan Shuptar, BS, MT(ASCP)  
Graham H. White, PhD, MAACB, FNACB, FFSc(RCPA)

### Abstract

Clinical and Laboratory Standards Institute document GP47—*Management of Critical- and Significant-Risk Results* describes systems for effective communication of laboratory results that need urgent clinical review. These laboratory results signify risk of major adverse patient outcomes. Therefore, mechanisms for their rapid identification and timely reporting are essential for patient safety. This guideline emphasizes management responsibilities for the development of the policy, the process, procedures, job descriptions, and monitoring systems that promote effective, timely reporting and compliance with regulatory requirements.

Clinical and Laboratory Standards Institute (CLSI). *Management of Critical- and Significant-Risk Results*. 1st ed. CLSI guideline GP47 (ISBN 1-56238-919-X [Print]; ISBN 1-56238-920-3 [Electronic]). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2015.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org).

**If you or your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at:**

**P:** +1.610.688.0100 **F:** +1.610.688.0700 **E:** [customerservice@cls.org](mailto:customerservice@cls.org) **W:** [www.clsi.org](http://www.clsi.org)



This is a preview. [Click here to purchase the full publication.](#)

Copyright ©2015 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

## Suggested Citation

CLSI. *Management of Critical- and Significant-Risk Results*. 1st ed. CLSI guideline GP47. Wayne, PA: Clinical and Laboratory Standards Institute; 2015.

ISBN 1-56238-919-X (Print)

ISBN 1-56238-920-3 (Electronic)

ISSN 1558-6502 (Print)

ISSN 2162-2914 (Electronic)

Volume 35, Number 18

.....

# Committee Membership

## Consensus Committee on Quality Management Systems and General Practices

**Tania Motschman, MS, MT(ASCP)SBB, CQA(ASQ)**  
**Chairholder**  
**Laboratory Corporation of America**  
**USA**

**Anne T. Daley, MS, CMQOE(ASQ), CSSBB, CLC(AMT), MT(ASCP), DLM**  
**Vice-Chairholder**  
**Chi Solutions, Inc.**  
**USA**

Deirdre Astin, MS, MT(ASCP)  
New York State Department of Health  
USA

Michael B. Cohen, MD  
ARUP Laboratories  
USA

Dennis J. Ernst, MT(ASCP)  
Center for Phlebotomy Education  
USA

Karen Heaton, MLT(CMLTA)  
Alberta Health Services  
Canada

Michelle Jenkins, MS, MT(AMT),  
CQE(ASQ), CMQ/OE  
Abbott  
USA

Debra Kuehl, MS, M(ASCP)  
Centers for Disease Control and  
Prevention  
USA

Joshua D. Levin, PhD  
FDA Center for Devices and  
Radiological Health  
USA

Michelle McLean, MS, MT(ASCP)  
Greiner Bio-One North America Inc.  
USA

Melissa Singer, MT(ASCP)  
Centers for Medicare & Medicaid  
Services  
USA

Janette Wassung  
PathCare Pathology Laboratory  
South Africa

Ginger Wooster, MBA, MT(ASCP)  
Orchard Software Corp  
USA

## Document Development Committee on Reporting Critical Laboratory Results

**Andrew N. Young, MD, PhD**  
**Chairholder**  
**Quest Diagnostics**  
**USA**

**Anand Dighe, MD, PhD**  
**Vice-Chairholder**  
**Massachusetts General Hospital**  
**USA**

**Christine M. Gryko, MT(ASCP)**  
**Committee Secretary**  
**Roswell Park Cancer Institute**  
**USA**

Graham Beastall, PhD, FRCPath  
International Federation of Clinical  
Chemistry  
Italy

Pilar Fernandez-Calle, MD, PhD  
La Paz University Hospital  
Spain

Peter Heseltine, MD, FACP, FACB, FIDSA  
UCI Medical Center (University of  
California, Irvine)  
USA

Andrea Rita Horvath, MD, PhD  
SEALS North, Prince of Wales Hospital  
Australia

Devery Howerton, PhD, MS,  
MT(ASCP)SI  
USA

Neal Kachalia, MT(ASCP), DLM, MBA  
Harris County Hospital District  
USA

Raouf E. Nakhleh, MD  
College of American Pathologists  
USA

Graham H. White, PhD, MAACB,  
FNACB, FFSc(RCPA)  
Flinders Medical Centre  
Australia

**Staff**  
Clinical and Laboratory Standards  
Institute  
USA

Marcy L. Hackenbrack, MCM, M(ASCP)  
*Project Manager*

Megan L. Tertel, MA, ELS  
*Editorial Manager*

Joanne P. Christopher, MA, ELS  
*Editor*

Alexander B. Phucas  
*Editor*

# Acknowledgment

CLSI, the Consensus Committee on Quality Management Systems and General Practices, and the Document Development Committee on Reporting Critical Laboratory Results gratefully acknowledge the following volunteers for their important contributions to the development of this document:

Lydia C. Contis, MD  
University of Pittsburgh Medical Center  
USA

Jennifer F. Rhamy, MBA, MA, MT(ASCP), SBB, HP  
St. Mary's Hospital  
USA

Michael J. Misialek, MD  
Newton-Wellesley Hospital  
USA

Susan Shuptar, BS, MT(ASCP)  
Memorial Sloan Kettering Cancer Center  
USA

# Contents

|                                                                                                                          |     |
|--------------------------------------------------------------------------------------------------------------------------|-----|
| Abstract .....                                                                                                           | i   |
| Committee Membership .....                                                                                               | iii |
| Foreword .....                                                                                                           | vii |
| Chapter 1: Introduction .....                                                                                            | 1   |
| 1.1 Scope .....                                                                                                          | 2   |
| 1.2 Background .....                                                                                                     | 2   |
| 1.3 Terminology .....                                                                                                    | 3   |
| Chapter 2: Development of an Organizational Process for Managing Critical- and Significant-Risk Laboratory Results ..... | 9   |
| 2.1 Developing Critical- and Significant-Risk Alert Lists and Thresholds .....                                           | 11  |
| 2.2 The Critical- and Significant-Risk Reporting Process .....                                                           | 22  |
| 2.3 Critical- and Significant-Risk Process Is Implemented .....                                                          | 33  |
| 2.4 Critical- and Significant-Risk Result Process Is Monitored .....                                                     | 39  |
| Chapter 3: Quality System Essentials for Managing Critical- and Significant-Risk Laboratory Results .....                | 43  |
| 3.1 Organization .....                                                                                                   | 44  |
| 3.2 Customer Focus .....                                                                                                 | 44  |
| 3.3 Personnel .....                                                                                                      | 45  |
| 3.4 Purchasing and Inventory .....                                                                                       | 45  |
| 3.5 Equipment .....                                                                                                      | 45  |
| 3.6 Process Management .....                                                                                             | 49  |
| 3.7 Documents and Records .....                                                                                          | 49  |
| 3.8 Information Management .....                                                                                         | 50  |
| 3.9 Nonconforming Event Management .....                                                                                 | 51  |
| 3.10 Assessments .....                                                                                                   | 52  |
| 3.11 Continual Improvement .....                                                                                         | 52  |
| Chapter 4: Conclusion .....                                                                                              | 53  |
| Chapter 5: Supplemental Information .....                                                                                | 55  |
| References .....                                                                                                         | 56  |
| Appendix A. Different Terms Used for Critical- and Significant-Risk Laboratory Results .....                             | 60  |
| Appendix B. US Benchmark Data From the College of American Pathologists .....                                            | 61  |
| Appendix C. Sample Documents Related to the Reporting of Critical- and Significant-Risk Results .....                    | 65  |

# Contents (Continued)

**Appendix D.** Regulatory and Accreditation Requirements .....68

**Appendix E.** Critical- and Significant-Risk Results in Infectious Disease, Hematology/Oncology, and Transplantation Medicine ..... 74

**Appendix F.** Critical- and Significant-Risk Results in Transfusion Medicine .....75

**Appendix G.** Critical- and Significant-Risk Results in Anatomic Pathology.....76

**Appendix H.** Sample Escalation Protocol Process.....80

**Appendix I.** Example of a Tool for Quality Monitoring of the Management of Critical- and Significant-Risk Results .....82

**The Quality Management System Approach** .....84

**Related CLSI Reference Materials** .....86

## Foreword

The timely reporting of results that need urgent clinical review is a fundamental responsibility of medical laboratories. This practice is essential for patient safety and is mandated by regulatory and accreditation requirements for laboratories and health care organizations. Laboratory and anatomic pathology results need urgent clinical review when they represent a high risk to patient health and safety. When the results indicate risk of immediately life-threatening conditions, they need to be communicated without delay to a responsible caregiver for urgent patient evaluation and management. GP47 recommends this result category be called “critical-risk” results. In addition, the concept of patient risk can be applied to a broader range of results that may not be immediately life-threatening, but still represent a risk to patients unless they are clinically evaluated and managed within a specific time frame sooner than would occur through routine reporting. GP47 recommends that this result category be called “significant-risk” results.

Due to the high risk to patient safety and the need for timely communication, the reporting of critical- and significant-risk results typically involves special procedures characterized by:

- ▶ Direct, person-to-person communication
- ▶ Verification of accurate receipt of information
- ▶ Occurrence within clinically appropriate time frames
- ▶ Documentation in the patient record

Many regulatory and accreditation organizations require processes for reporting results that need urgent clinical review as well as monitoring systems and quality goals to ensure reporting is timely and effective. Compliance with these regulatory and accreditation requirements is often a focal point during inspections of laboratories and health care organizations.

This guideline defines key processes in the reporting of critical- and significant-risk laboratory results. It recommends processes and procedures that are compliant with regulatory and accreditation requirements and consistent with patient safety best practices.

**NOTE:** The findings and conclusions in this document are those of the authors and do not necessarily reflect the views of the organizations they represent.

### KEY WORDS

Alert lists

Alert thresholds

Communication

Critical-risk results

Critical values

Patient safety

Quality management

Risk management

Significant-risk results

This page is intentionally left blank.

# Chapter 1

## Introduction

This chapter includes:

- ▶ Document scope and applicable exclusions
- ▶ Background information pertinent to the document content
- ▶ “Note on Terminology” that highlights particular use and/or variation in use of terms and/or definitions
- ▶ Terms and definitions used in the document
- ▶ Abbreviations and acronyms used in the document



This is a preview. [Click here to purchase the full publication.](#)